American College of Cardiology 2011

Lipid Management in Special Populations

Statins are the most widely prescribed agents in the world. While muscle-related adverse effects associated with statins are well known, accurately quantifying their incidence to guide clinicians with respect to lipid management can be difficult, said Richard H. Karas, MD, PhD, Tufts Medical Center, Boston, at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Low-Dose Aspirin plus Fixed-Dose Naproxen/Esomeprazole Found Noninferior to Low-Dose Aspirin Alone in Effects on Platelet Inhibition

The effect of a fixed-dose combination of naproxen and esomeprazole on cyclooxygenase-1 (COX-1) inhibition by low-dose aspirin was found to be noninferior to low-dose aspirin alone in healthy subjects, according to the results of a Phase 1 study presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Outpatient Low-Molecular Weight Heparin Periprocedural Management as Effective as Inpatient IV Unfractionated Heparin

Low-molecular weight heparin was shown to be as effective as inpatient IV unfractionated heparin management in mechanical heart valve patients requiring interruption of chronic anticoagulation for an invasive procedure, according to study results presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Adding Aldosterone to Angiotensin Blockade Improves Coronary Endothelial Function Improves in Women

A study presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session, revealed that administering a combination of aldosterone and angiotensin blockade for 4 months improves endothelial function compared with angiotensin blockade alone in women with signs and symptoms of ischemia and endothelial dysfunction.

Dabigatran Superior to Warfarin in Patients with Atrial Fibrillation and Lower CHA2DS2-VASc Scores

Dabigatran 150mg was superior to warfarin and dabigatran 110mg was noninferior to warfarin for preventing stroke in patients with atrial fibrillation (AF) regardless of CHA2DS2-VASc scores, as shown by the results of a subgroup analysis of the RE-LY trial presented today at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Optimal Treatment Outlined for Patients with Heart Failure and Serious Comorbidities, Including “Diabesity”

Investigators at the forefront of treating the patient with heart failure (HF) and concomitant diabetes, obesity, depression, sleep apnea, left ventricular (LV) hypertrophy or renal insufficiency presented the latest management findings today at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.